Seller record · Telehealth service

Amble

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: Every reference is to a pharmacy network provider, and no facility is named. The terms, questions, safety, refund and privacy surfaces carry it. 1 more criterion also fails; see the table below.

At a glance

AmbleTelehealth service

6/8criteria passed

Price: $179 a month, $135 on a six-month plan
Sells: compounded semaglutide, compounded tirzepatide, NAD+, and 3 more
FDA letters: None on file

Visit Amble See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 drugs alongside NAD+, sermorelin, glutathione and lipotropic injections. Its plan table prints three monthly rungs, and a fourth figure sits in the page markup where no reader can see it.

Operating entity Amble Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Amble's FAQ
S2	Prescription gating	PASS	Amble's GLP NAD+ new page on its sign-up site
S3	Pharmacy identification	FAIL	Amble's terms of service page
S4	Compounding disclosure	PASS	Amble's GLP-1 injections page
S5	Analytical documentation	FAIL	Amble's FAQ
S6	Business address	PASS	Amble's terms of service page
S7	Price disclosure	PASS	Amble's GLP-1 injections page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe questions page states that a state-licensed physician reviews the questionnaire, completes a clinical evaluation and, where state law requires, holds a live consultation.Source: Amble's FAQ.

S2PASSAn enrollment intake asking the weight-loss goal comes before any product page and before any payment field.Source: Amble's GLP NAD+ new page on its sign-up site.

S3FAILEvery reference is to a pharmacy network provider, and no facility is named. The terms, questions, safety, refund and privacy surfaces carry it.Source: Amble's terms of service page.

S4PASSThe GLP-1 product page states that compounded drugs are not Food and Drug Administration approved and do not undergo clinical studies for safety and efficacy.Source: Amble's GLP-1 injections page.

S5FAILNo certificate, lot number or purity figure appears on the site.Source: Amble's FAQ.

S6PASSThe terms print two street addresses, a Madison Avenue suite in New York and a Warren Road address in Cortland, Ohio, the second of which is given for written notice.Source: Amble's terms of service page.

S7PASSThe GLP-1 page prints three rungs at the same price for any dose: 179 dollars for one month, 160 dollars for three months and 135 dollars for six months. A fourth figure sits in the page markup inside a container set to display none, which no control on the page reveals, so it is not a published price and is not recorded as one.Source: Amble's GLP-1 injections page.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+, sermorelin, glutathione, lipotropic injections.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione

Visit Amble

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.